EA201791382A1 - Стабильная лекарственная форма замороженного вируса простого герпеса - Google Patents

Стабильная лекарственная форма замороженного вируса простого герпеса

Info

Publication number
EA201791382A1
EA201791382A1 EA201791382A EA201791382A EA201791382A1 EA 201791382 A1 EA201791382 A1 EA 201791382A1 EA 201791382 A EA201791382 A EA 201791382A EA 201791382 A EA201791382 A EA 201791382A EA 201791382 A1 EA201791382 A1 EA 201791382A1
Authority
EA
Eurasian Patent Office
Prior art keywords
drug form
stable drug
simple herpes
frozen virus
virus
Prior art date
Application number
EA201791382A
Other languages
English (en)
Inventor
Дженнифер Р. Литовски
Кристин Клаудия Сиска
Брюс Артур Кервин
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA201791382A1 publication Critical patent/EA201791382A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Композиция живого вируса, которая сохраняет инфекционность и обеспечивает улучшенную стабильность вируса во время одного или более циклов замораживания/размораживания и/или при длительном хранении в жидком состоянии при температурах от чуть выше температуры замерзания до температуры окружающей среды.
EA201791382A 2014-12-18 2015-12-15 Стабильная лекарственная форма замороженного вируса простого герпеса EA201791382A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093663P 2014-12-18 2014-12-18
PCT/US2015/065858 WO2016100364A1 (en) 2014-12-18 2015-12-15 Stable frozen herpes simplex virus formulation

Publications (1)

Publication Number Publication Date
EA201791382A1 true EA201791382A1 (ru) 2017-10-31

Family

ID=55229814

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791382A EA201791382A1 (ru) 2014-12-18 2015-12-15 Стабильная лекарственная форма замороженного вируса простого герпеса

Country Status (19)

Country Link
US (2) US20170360857A1 (ru)
EP (1) EP3234114B9 (ru)
JP (2) JP6975041B2 (ru)
KR (2) KR20230107375A (ru)
CN (1) CN107580626A (ru)
AU (2) AU2015362687B2 (ru)
BR (1) BR112017013009A2 (ru)
CA (1) CA2971201A1 (ru)
CL (1) CL2017001563A1 (ru)
CO (1) CO2017007086A2 (ru)
EA (1) EA201791382A1 (ru)
ES (1) ES2948037T3 (ru)
HK (1) HK1245823A1 (ru)
IL (3) IL300202B2 (ru)
MA (1) MA40948A (ru)
MX (2) MX2017008013A (ru)
SG (1) SG11201704975SA (ru)
WO (1) WO2016100364A1 (ru)
ZA (1) ZA201704695B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017013421A1 (en) * 2015-07-20 2017-01-26 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood
WO2019213509A1 (en) * 2018-05-03 2019-11-07 Rutgers, The State University Of New Jersey Compositions and methods for treating cancer
CN109161562A (zh) * 2018-08-09 2019-01-08 湖北科技学院 一种选择性杀灭肝癌细胞的新型溶瘤病毒及其构建方法
JP2022516077A (ja) * 2018-12-27 2022-02-24 アムジェン インコーポレイテッド 凍結乾燥ウイルス製剤
WO2022006745A1 (en) * 2020-07-07 2022-01-13 Oriengene Biotechnology Ltd Guide rna for hsv-1 gene editing and method thereof
CN116421734A (zh) * 2021-12-30 2023-07-14 深圳复诺健生物科技有限公司 适用于溶瘤病毒的冻干保护剂及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63307827A (ja) * 1987-06-08 1988-12-15 Kitasato Inst:The 安定化された生ウイルスワクチンおよびその製造法
US6770274B1 (en) 1990-09-14 2004-08-03 The General Hospital Corporation Viral mutant HSV mediated destruction of neoplastic cells
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5585096A (en) 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US6699468B1 (en) 1994-06-23 2004-03-02 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US5824318A (en) 1996-07-24 1998-10-20 American Cyanamid Company Avirulent herpetic viruses useful as tumoricidal agents and vaccines
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6379674B1 (en) 1997-08-12 2002-04-30 Georgetown University Use of herpes vectors for tumor therapy
US6210683B1 (en) * 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
CA2356937A1 (en) 1998-12-31 2000-07-13 Richard J. Whitley Recombinant herpes simplex virus useful for treating neoplastic disease
AU2905199A (en) 1999-03-15 2000-10-04 Trustees Of The University Of Pennsylvania, The Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6764675B1 (en) 1999-06-08 2004-07-20 The Uab Research Foundation Herpes simplex virus expressing foreign genes and method for treating cancers therewith
MXPA02001911A (es) 1999-08-24 2003-07-21 Medarex Inc Anticuerpos ctla-4 humanos y sus usos.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP4212897B2 (ja) 2001-03-27 2009-01-21 具紀 藤堂 ウイルスおよび治療法におけるそれらの使用
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CA2479763A1 (en) * 2002-03-27 2003-10-09 Baylor College Of Medicine Potent oncolytic herpes simplex virus for cancer therapy
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
US7731952B2 (en) 2004-06-24 2010-06-08 New York University Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
CN101230334B (zh) 2007-01-22 2011-06-01 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
CN101230335B (zh) 2007-01-22 2010-08-11 北京奥源和力生物技术有限公司 单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
HUE031617T2 (en) * 2007-04-06 2017-07-28 Takeda Vaccines Inc Methods and preparations for live attenuated viruses
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
DK2342226T3 (en) 2008-09-26 2016-09-26 Dana Farber Cancer Inst Inc HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
US20130202639A1 (en) * 2010-03-25 2013-08-08 Konstantin G. Kousoulas Synthetic Herpes Simplex Viruses for Treatment of Cancers
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CN101926990A (zh) * 2010-09-21 2010-12-29 中山大学 肿大细胞病毒vsocs基因缺失减毒活疫苗及其制备方法和应用
WO2013006795A2 (en) 2011-07-07 2013-01-10 Humanitas International Foundation Antiviral compositions and methods of their use
CA2859916C (en) * 2012-01-09 2021-02-09 Sanofi Pasteur Biologics, Llc Purification of herpes virus
CA2873775C (en) * 2012-05-21 2021-04-20 Sanofi Pasteur Limited Herpesvirus compositions and related methods
WO2014036412A2 (en) * 2012-08-30 2014-03-06 Amgen Inc. A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor

Also Published As

Publication number Publication date
JP6975041B2 (ja) 2021-12-01
EP3234114A1 (en) 2017-10-25
IL252942A0 (en) 2017-08-31
CA2971201A1 (en) 2016-06-23
AU2015362687A1 (en) 2017-07-06
JP2021072795A (ja) 2021-05-13
AU2022201523A1 (en) 2022-03-24
IL300202A (en) 2023-03-01
MA40948A (fr) 2017-10-25
US20210052680A1 (en) 2021-02-25
EP3234114B9 (en) 2023-06-14
JP2018502078A (ja) 2018-01-25
WO2016100364A1 (en) 2016-06-23
US20170360857A1 (en) 2017-12-21
KR20230107375A (ko) 2023-07-14
AU2015362687B2 (en) 2021-12-09
CO2017007086A2 (es) 2017-10-10
ES2948037T3 (es) 2023-08-30
MX2017008013A (es) 2018-03-06
IL300202B1 (en) 2023-12-01
CL2017001563A1 (es) 2018-01-26
KR20170095270A (ko) 2017-08-22
EP3234114B1 (en) 2023-04-12
CN107580626A (zh) 2018-01-12
MX2023012564A (es) 2023-11-08
KR102549746B1 (ko) 2023-07-03
IL308119A (en) 2023-12-01
BR112017013009A2 (pt) 2018-06-26
HK1245823A1 (zh) 2018-08-31
ZA201704695B (en) 2023-12-20
SG11201704975SA (en) 2017-07-28
IL300202B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
EA201791382A1 (ru) Стабильная лекарственная форма замороженного вируса простого герпеса
DK3656869T3 (da) Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering
DK3303958T3 (da) Massegodsfrysetørring ved anvendelse af sprøjtefrysning og tørring under omrøring med varme
FR3042253B1 (fr) Cuve etanche et thermiquement isolante
BR112015030374A2 (pt) solução contendo trealose e dextrana para transplante de células mamíferas
DK3127428T3 (da) Anvendelse af forgreningsenzym ec 2.4.1.18 til forbedring af sammenhængskraft i brød
UY35862A (es) Formulaciones listas de fertilizante líquido de bifentrina
PL3277406T3 (pl) Pochłaniacz NOx z mieszanki ubogiej o zwiększonej wydajności w wysokich i niskich temperaturach
WO2014186754A3 (en) Dry solid aluminum adjuvant-containing vaccines and related methods thereof
CL2016002337A1 (es) Uso de derivados de trifluoroetilsulfóxido sustituidos con n-arilamidina para combatir parásitos mediante riego, aplicación por goteo, aplicación por inmersión, inyección en el suelo o mediante el tratamiento de semillas
EA201891064A1 (ru) Способ получения осушенных микробных клеток
GB2518080A (en) Vessel of thermally conductive plastic for freeze - drying
UY37047A (es) Tratamiento in situ de semillas en el surco
DK3419435T3 (da) Frysekoncentration af rod- eller knoldsaft
BR112017026666A2 (pt) armazenagem de longo prazo e conservação de plaquetas
CL2017000207A1 (es) Zwitteriones derivados de disulfuro de carbono
DK3368052T3 (da) Anvendelse af mapk-hæmmere for at nedbringe tabet af hæmatopoietiske stamceller under ex vivo-dyrkning og -genmanipulation
WO2014045202A3 (en) Cell preparation method
DK3356524T3 (da) Forøget genlevering til naturlige dræberceller, hæmatopoietiske stamceller og makrofager
CL2016002259A1 (es) Procedimiento para preparar huevos fritos congelados
DK3194602T3 (da) Forbindelser og fremgangsmåder til at forstærke virusgenoverførsel til humane hæmatopoietiske celler
TWD168034S (zh) 凍結保存容器
DK3397270T3 (da) Sammensætninger til anvendelse i behandlingen af hunters syndrom
BR112016028662A2 (pt) composições herbicidas sólidas contendo um agente de proteção
EA201890136A1 (ru) Молекула нуклеиновой кислоты для обеспечения инсектицидных свойств у растений